rbbp7 Antibody

Cancer Biology

• Esophageal Squamous Cell Carcinoma (ESCC): RBBP7 overexpression correlates with poor prognosis, advanced lymph node involvement, and increased metastasis. Knockdown experiments in ESCC cell lines (TE1, Eca109) reduced migration and invasion by 40–60%, while overexpression in KYSE30/KYSE150 cells enhanced these processes .

• Mechanistic Role: RBBP7 promotes epithelial-mesenchymal transition (EMT) by repressing E-cadherin transcription and modulating MMP9 activity via the RECK pathway .

Neurodegenerative Diseases

• Alzheimer’s Disease (AD): Reduced RBBP7 levels in AD patient brains correlate with increased tau acetylation (lysine 280) and phosphorylation (AT8, AT100 sites). Overexpression in PS19 tauopathy mice reduced neuronal death by 30–50% and rescued tau-induced cytotoxicity in vitro .

Technical Validation Data

The antibody’s specificity has been confirmed through:

• Western Blot: Clear 48 kDa band in human HeLa, mouse NIH/3T3, and rat spleen lysates, absent in RBBP7-knockout HAP1 cells .

• Immunoprecipitation (IP): Successful pull-down of RBBP7 from HeLa and NIH/3T3 lysates, with no cross-reactivity observed in IgG controls .

• Immunohistochemistry (IHC): Nuclear staining in human lung cancer, mouse lung, and rat lung tissues .

Clinical and Experimental Relevance

Limitations and Considerations

• Tissue Specificity: RBBP7’s role varies by cancer type (e.g., tumor-suppressive in breast cancer vs. pro-metastatic in ESCC) .

• Antibody Cross-Reactivity: Validated only for human, mouse, and rat samples; untested in other species .